Katkhuda covers the Healthcare sector, focusing on stocks such as Eledon Pharmaceuticals, Disc Medicine, and Vera Therapeutics. According to TipRanks, Katkhuda has an average return of 34.4% and a 56.32% success rate on recommended stocks.
In a report released on August 20, H.C. Wainwright also reiterated a Buy rating on the stock with a $55.00 price target.
Based on Amylyx Pharmaceuticals Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $43.42 million. In comparison, last year the company had a GAAP net loss of $41.44 million
Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AMLX in relation to earlier this year. Most recently, in May 2026, Karen Firestone, a Director at AMLX bought 3,800.00 shares for a total of $51,338.00.
